Horizon Pharma PLC (NASDAQ:HZNP) reported Q3 earnings that exceeded analysts' estimates and as it raised its guidance for 2014. HZNP is trading in the upper half of the 52-week range between $3.70 and $18.30. The biopharmaceutical company said adjusted net income was $0.24 per diluted share compared to a loss of $0.03 a year ago and better than the $0.14 average estimate from analysts polled by Capital IQ. Revenue more than tripled to $75.1 million from $24.1 million compared to the $73.7 million consensus estimate.Reported net income was $2.06 million or $0.02 per diluted share compared to a loss of $5.5 million or $0.08 the year earlier. For 2014, Horizon Pharma PLC (NASDAQ:HZNP) now expects sales between $280 million and $290 million, up from the previous guidance between $270 million and $280 million and ahead of he $277 million consensus. In 2015, it is now expecting sales between $425 million and $450 million, up from previously $380 million to $405 million and compared to the $389 million consensus.Mast Therapeutics Inc (NYSEMKT:MSTX) a clinical-stage biopharmaceutical company, has announced the pricing of an underwritten public offering that is expected to raise gross proceeds of approximately $21 million. The offering is expected to close on or about November 12, 2014, subject to customary closing conditions. All of the securities in the offering are being sold by Mast Therapeutics Inc (NYSEMKT:MSTX).The company said that it expects to receive net proceeds from the offering of approximately $20 million, after deducting underwriting discounts and commissions and estimated offering expenses. It said that it intends to use the net proceeds primarily to fund its clinical development programs, including EPIC, the company's ongoing pivotal Phase 3 study of MST-188 in sickle cell disease, and for working capital and general corporate purposes. Over the past 52 weeks, the company has traded between $0.40 and $1.10.Teradata Corporation (NYSE:TDC) reported Q3 earnings that beat analysts' expectations. TDC is trading in the lower half of the 52-week range between $37.66 and $49.57. The provider of analytic data solutions said non-GAAP net income rose to $0.71 per diluted share from $0.70 the year earlier, exceeding the $0.66 average estimate from analysts polled by Capital IQ. Revenue was near unchanged at $667 million compared to $666 million a year ago and was slightly shy of the $668.6 million consensus.Reported net income fell to $94 million from $98 million but edged higher to $0.60 per diluted share from $0.59 a year ago on a lower share count. For 2014, Teradata Corporation (NYSE:TDC) said it still expects 2014 constant currency revenue growth at the low end of its original 3% to 7% guidance range. it noted that based on currency rates at the end of October, currency translation is now expected to have a 1 percentage point headwind on Teradata's full-year revenue comparison. It also said it still expects non-GAAP EPS to be at the lower end of its $2.85 to $3.00 range. Analysts are expecting EPS of $2.87.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
